Hemab Therapeutics Quarterly Balance Sheet
NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Hemab Therapeutics financial position
As of Jun 30, 2026, Hemab Therapeutics reported total assets of $467.8 million against total liabilities of $13.5 million. Shareholders' equity stood at $454.3 million, or 97.1% of assets. The company held $237.4 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 35.85, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Hemab Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Cash & Equivalents | 237.37M | 49.86M | — | — |
| Short-Term Investments | 220.09M | 113.67M | — | — |
| Total Current Assets | 464.00M | 169.43M | — | — |
| Property, Plant & Equipment | 596.00K | 648.00K | — | — |
| Total Assets | 467.78M | 175.26M | — | — |
| Accounts Payable | 6.23M | 5.68M | — | — |
| Total Current Liabilities | 12.94M | 13.19M | — | — |
| Total Liabilities | 13.51M | 13.71M | — | — |
| Shareholders' Equity | 454.27M | -198.62M | -141.47M | -129.15M |
| Retained Earnings | -228.69M | -204.54M | — | — |
| Net Cash (Debt) | 457.46M | 163.53M | — | — |
This table shows 4 quarterly periods of Hemab Therapeutics's balance sheet, from Q2 2026 back to Q? 2025, across 11 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow COAG's reporting calendar. What is a balance sheet?